Merus

140 articles about Merus

• Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

  12/6/2021

  Merus N.V. today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.

• Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021

  12/2/2021

  Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors.

• Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

  11/10/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference.

• Merus Announces Pricing of Public Offering of Common Shares - Nov 05, 2021

  11/5/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share.

• Merus N.V. Announces Proposed Public Offering of Common Shares - Nov 04, 2021

  11/4/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the launch of a proposed underwritten public offering of its common shares.

• Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update

  11/2/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced a regulatory update for the zenocutuzumab program in NRG1 positive solid tumors, financial results for the third quarter that ended September 30, 2021, and provided a business update.

• Merus to Participate in Upcoming Investor Conferences in September 2021

  9/7/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in the following investor conferences.

• Merus Announces Financial Results for the Second Quarter 2021 and Provides Business Update

  8/5/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the second quarter that ended June 30, 2021 and provided a business update.

• Merus to Participate in William Blair's Biotech Focus Conference 2021

  7/7/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a panel discussion, Moving Beyond Monoclonals: The Potential of Multispecific Therapies, at William Blair's Biotech Focus Conference 2021 on Wednesday, July 14 at 11:20 a.m. ET.

• Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

  6/4/2021

  -  61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date -  Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across several NRG1+ tumor types (29%) -  Zenocutuzumab continues to be well tolerated with a favorable safety profile

• Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

  5/19/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the publication of the abstract highlighting interim data, as of a January 12, 2021 cutoff, from the phase 1/2 eNRGY trial and Early Access Program of bispecific antibody zenocutuzumab in patients with NRG1+ cancers, on the ASCO website.

• Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial

  5/13/2021

  Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ®  and Triclonics ® ), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody

• Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

  5/11/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET.

• Merus Announces Financial Results for the First Quarter 2021 and Provides Business Update

  5/6/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced financial results for the first quarter that ended March 31, 2021, and provided a business update.

• Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update

  3/16/2021

  Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021 Clinical update planned for MCLA-145 in 2H 2021 MCLA-129 expected to enter clinic in the United States in 2021

• Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference

  3/8/2021

  Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET.

• Merus to Participate in Upcoming Investor Conferences - Feb 01, 2021

  2/1/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:

• Merus Announces Pricing of Public Offering of Common Shares - Jan 21, 2021

  1/21/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an underwritten public offering of 4,848,485 common shares at a public offering price of $24.75 per share.

• Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial

  1/12/2021

  Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness of the eNRGy trial and to provide molecular screening opportunities for patients with cancers that may have neuregulin 1 fusions.

• Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium

  1/11/2021

  Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics™), today announced that clinical data from its Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium (ASCO G